Across TCGA pan-cancer cohorts, IGKV2D-23 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of IGKV2D-23’s most consistent transcriptional readouts.
The strongest signal is observed in thyroid carcinoma (THCA), where IGKV2D-23 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types IGKV2D-23 is over-expressed in tumor.
THCA are the cancer types where IGKV2D-23 tumor–normal differential expression is most reproducible.